DNER and pulmonary arterial hypertension: First, for both drugs, their therapeutic roles emphasized the importance of endothelial pathobiology in PH, with both long-term and immediate translational implications, as early human clinical trials are underway for BET inhibitors in PAH (NCT03655704).